Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab in advanced solid tumors
NCT03312842Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sugemalimab in solid tumor (advanced stage), sponsored by CStone Pharmaceuticals. Primary endpoints: Safety and Tolerability of CS1001 and Maximum Tolerated Dose and/or Recommended Phase II Dose. Started Oct 2017; status: completed.
02
Drugs
sugemalimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03312842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312842.